About
Ebooks
The Cornerstones of Cell Therapy Excellence
The Cornerstones of Cell Therapy Excellence, explores analytical, process development, quality, and manufacturing approaches that enable sustainable progress from early development through...
Purpose-Built U.S. Facilities Designed for Scalable Cell Therapy Manufacturing
Kincell Bio’s GMP cell therapy manufacturing facilities are engineered to support early-phase through commercial production, with flexibility, control, and inspection-readiness. Our flexible suites, which utilize single-use equipment, robust quality systems, and an integrated analytics infrastructure, enable reliable, scalable manufacturing for autologous and allogeneic programs.
Facilities & Teams Supporting Cell
Therapies’ Full Lifecycle
Gainesville, FL, USA
Gainesville, FL, USA
The Gainesville facility and team specialize in supporting early-phase cell therapy CMC with flexible GMP suites, integrated analytical labs, and process development capabilities designed to accelerate IND readiness and clinical manufacturing.
Facility Focus
- Development, QC, and clinical-phase cGMP manufacturing
- Early-phase process and analytical development
- Process transfer, confirmation, and optimization
- Scale-up studies for manufacturing readiness
- Designed for multi-product production
- QC testing and stability studies
Cell Therapy Produced
- Allogeneic and autologous cell therapies
- CAR-T
- CAR-M
- CAR-NK
- TCR-T
- Differentiated iPSC
- TRegs
Facility Stats
- 29,000 ft2 campus, including 7,500 ft2 expansion space
- 4 flexible GMP manufacturing suites outfitted with single-use equipment
- 1,500 ft2 cGMP manufacturing
- 3 labs (QC, analytical, and process development) totaling 2,000+ ft2
- 2,200 ft2 warehouse for ambient, refrigerated, -80° C & LN2 storage
Research Triangle Park, NC, USA
Research Triangle Park, NC, USA
Our Research Triangle Park facility supports pivotal and commercial cell therapy programs with flexible GMP suites, advanced analytics, in-process and release testing, and expansion opportunities, providing the infrastructure for reliable long-term supply.
Facility Focus
- Equipment to support in-process and release testing
- Clinical and registrational GMP manufacturing
- Designed for multi-product production
- Flexible suites, single-use equipment
- Robust analytical technology
- Opportunities for modular cleanroom expansion
- Additional storage capacity for stability and long-term cold storage
Cell Therapy Produced
- Allogeneic and autologous cell therapies
- CAR-T
- CAR-M
- CAR-NK
- TCR-T
- Differentiated iPSC
- TRegs
Facility Stats
- 32,000 ft2 campus, including 15,000ft2 expansion space
- 4 flexible GMP manufacturing suites outfitted with single-use equipment
- 1,700 ft2 cGMP manufacturing
- QC labs
- GMP warehouse
- Cleanroom-dedicated air handlers, supports Grade B/ISO5, C/ISO7 and D/ISO8, and CNC
Integrated Capabilities for Full Lifecycle Cell Therapy Development
CMC
CMC Roadmap & Development
Kincell’s early-phase CMC roadmap aligns the TPP with process development, analytics, and regulatory strategies, building a structured, risk-managed path from concept to IND while keeping scalability and commercial viability at the forefront of decision making.
Analytics
Testing
Process Development
Manufacturing
Tech Transfer
Kincell Bio GMP Cell Manufacturing Facilities FAQs
How does Kincell Bio manage multi-product manufacturing to prevent cross-contamination?
Every product entering a Kincell Bio facility undergoes a thorough risk assessment to identify the specific control strategies required. The team evaluates the product’s unique characteristics and then applies a combination of physical and temporal segregation techniques tailored to each program.
A key element of this strategy is our deliberate decision not to manufacture viral vectors on site. Viral vector manufacturing introduces microbial processes and large-scale, open processing, which significantly elevate the risk of contamination. By limiting viral vector use to small, carefully controlled amounts specific to individual products, Kincell maintains a tightly managed manufacturing environment that protects product integrity and patient safety across all concurrent programs.
What infrastructure does Kincell Bio have in place to protect patient material during manufacturing?
Because many cell therapy products are autologous, losing a batch carries consequences far beyond financial impact. It means a specific patient may not receive the treatment they need. We take this responsibility seriously and have designed our facilities with cleanrooms built to minimize the risk of disruption.
Our facilities are equipped with backup generators and uninterruptible power supply (UPS) systems at critical equipment stations. In the event of a power interruption, the UPS seamlessly bridges the gap until generator power is available or power is fully restored, protecting sensitive processes from even momentary power surges. Critical environmental parameters, such as temperature, differential pressure, and CO2 levels, are continuously monitored under quality oversight, ensuring that any excursion is detected and addressed immediately to safeguard the product and the patient.
What are Kincell Bio’s manufacturing facility specifications, and how is capacity assessed for new programs?
Kincell’s Gainesville, Florida, facility is largely focused on early-phase programs and currently features four ISO 7 cleanrooms, each approximately 400 to 500 square feet, with Grade A processing environments. The facility is implementing isolator filling technology and has approximately 7,500 square feet of available expansion space.
Our Research Triangle Park, North Carolina, facility is focused on later-stage and commercial-phase programs. It is a 32,000-square-foot campus, including four ISO 7 cleanrooms, with two additional cleanrooms made possible by the expansion currently underway.
Because every cell therapy process is unique, capacity is never assessed on a one-size-fits-all basis. When evaluating a new program, the team conducts a detailed process-specific assessment, including reviewing equipment requirements, suite layout, process duration, and patient ramp rates, to determine the most efficient and effective fit. This individualized approach ensures that capacity planning is realistic, right-sized, and fully aligned with each client’s clinical or commercial timeline.
What are the expansion plans currently underway at the Research Triangle Park, NC, facility?
In response to increasing market demand, we are currently undertaking a significant expansion of our RTP facility. The expansion will enable two additional ISO 7 cleanrooms, an additional QC lab, an MSAT lab, and a microbiology lab. We are also expanding our GMP warehouse, which will increase our storage capacity. The project involves building out the facility’s original gray space, square footage intentionally designed for future growth. These additions will enhance Kincell’s ability to support its growing portfolio of client programs across all development stages.
How does Kincell Bio’s geographic footprint support autologous cell therapy programs?
Geographic proximity is a meaningful operational consideration for autologous cell therapy manufacturing, where timing around the collection and return of patient material is often a critical factor. Kincell’s two sites are strategically positioned to serve a broad geographic area in the US.
The Gainesville, Florida, facility is well situated to serve the Southeast, while the Research Triangle Park, North Carolina, site is positioned to reach major hospital networks across the Mid-Atlantic and Northeast corridor. For programs requiring fresh leukapheresis material or time-sensitive product return, proximity to clinical sites reduces logistical risk and supports tighter turnaround timelines. Additionally, we are continually evaluating site opportunities in other regions, including the West Coast, to further expand our geographic reach and ensure programs are matched to the facility best suited to serve our clients’ patient populations.
Ebooks
Navigating Intensifying Cell Therapy Regulatory Expectations
In our new eBook, Navigating Intensifying Cell Therapy Regulatory Expectations, Kincell Bio’s scientific and executive leadership break down what’s changed, why programs...
Webinars
Advancing Cell Therapy Development with Integrated Analytical & Process Strategies
This webinar explores how integrated PD/AD expertise can deliver robust, regulatory-ready assays and accelerates cell therapy development.
Talk to an expert
Turning Cell Therapy Innovation Into Patient Impact
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields